Xeris Biopharma Holdings (XERS) Amortizatization of Intangibles (2020 - 2024)
Xeris Biopharma Holdings' (XERS) quarterly Amortizatization of Intangibles came in at $73000.0 in Q4 2024, down 50.0% YoY from $146000.0 in Q1 2024, and down 61.98% on a QoQ basis from $192000.0 in Q3 2024.
Xeris Biopharma Holdings (XERS) Amortizatization of Intangibles (2020 - 2024) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 5 years of Amortizatization of Intangibles data on file, last reported at $73000.0 in Q4 2024.
- Quarterly Amortizatization of Intangibles fell 50.0% year-over-year to $73000.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $73000.0 (down 91.1% YoY) and the FY2024 annual result came in at $747000.0, down 40.86% from the prior year.
- Amortizatization of Intangibles declined to $73000.0 in Q4 2024, from $192000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $430000.0 in Q2 2023 to a low of -$154000.0 in Q1 2021.
- A 5-year average of $75058.8 and a median of -$19000.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles jumped 1705.26% — and 2024, when it tumbled 51.83%.
- Tracing XERS's Amortizatization of Intangibles over 5 years: stood at -$137000.0 in 2020, then jumped by 56.2% to -$60000.0 in 2021, then jumped by 40.0% to -$36000.0 in 2022, then soared by 505.56% to $146000.0 in 2023, then slumped by 50.0% to $73000.0 in 2024.
- The last three Amortizatization of Intangibles figures came in at $73000.0 (Q4 2024), $192000.0 (Q3 2024), and $298000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.92 Bn | 42.96 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.53 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.87 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.22 Bn | 19.56 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.71 Bn | 17.83 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 900,000.00 |
| 8 | Elanco Animal Health | 11.80 Bn | 11.27 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.51 Bn | 1.39 Bn | 79.59 Mn | 176,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 73,000.00 |
| Dec 31, 2024 | 73,000.00 |
| Sep 30, 2024 | 192,000.00 |
| Sep 30, 2024 | 192,000.00 |
| Jun 30, 2024 | 298,000.00 |
| Jun 30, 2024 | 298,000.00 |
| Mar 31, 2024 | 184,000.00 |
| Mar 31, 2024 | 184,000.00 |
| Dec 31, 2023 | 146,000.00 |
| Dec 31, 2023 | 146,000.00 |
| Sep 30, 2023 | 305,000.00 |
| Sep 30, 2023 | 305,000.00 |
| Jun 30, 2023 | 430,000.00 |
| Jun 30, 2023 | 430,000.00 |
| Mar 31, 2023 | 382,000.00 |
| Mar 31, 2023 | 382,000.00 |
| Dec 31, 2022 | -36,000.00 |
| Dec 31, 2022 | -36,000.00 |
| Sep 30, 2022 | -19,000.00 |
| Sep 30, 2022 | -19,000.00 |